FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2317334758> ?p ?o ?g. }

• W2317334758 abstract "Previous studies have concluded that the mechanism responsible for the antineoplastic properties of NSAIDs is cyclooxygenase (COX) independent, which suggests that more selective drugs can be developed for cancer chemoprevention by targeting such mechanisms. With this paradigm, we are synthesizing novel sulindac derivatives that have reduced COX inhibitory activity, but enhanced tumor cell growth inhibitory activity. A prototypic dimethylethyl amide derivative referred to as sulindac sulfide amide (SSA) was previously reported to lack COX-1 or COX-2 inhibitory activity, yet have improved potency to inhibit tumor cell growth in vitro. For example, SSA inhibited the growth of human HT-29 colon tumor cells with IC 50 values of 1-2 µM compared with 70-90 µM for sulindac sulfide (SS), a non-selective COX inhibitor. SSA was also appreciably more effective than SS in inhibiting HT-29 colon tumor cell growth using a 3-dimensional in vitro tumor cell model. SSA induced apoptosis of HT-29 carcinoma cells, but normal human colonocytes were insensitive to treatment, suggesting an element of tumor selectivity. The mechanism of SSA induced apoptosis is associated with cGMP phosphodiesterase (PDE) inhibition, elevation of intracellular cGMP, and activation of protein kinase G, which also appears to be an important off-target effect of SS. SSA inhibited the growth of a variety of histologically diverse tumor cell lines, an effect that is consistent with studies showing the overexpression of PDE5 in various tumor types, including colorectal adenomas and carcinomas. SSA was well tolerated in the FCCC Min mouse model in which oral administration reduced colon tumor multiplicity by approximately 80% and tumor incidence by 50%. SSA also inhibited tumor growth in the human HT-29 colon mouse xenograft model by approximately 60%, while sulindac at its maximum tolerated dose was marginally effective. The antitumor activity of SSA in the HT-29 model was accompanied by decreased numbers of proliferating cells and increased numbers of apoptotic cells as determined by immunohistochemistry. Pharmacokinetic studies in mice bearing HT-29 xenografts revealed that plasma and tumor levels of SSA from a tolerated dose of SSA appreciably exceeded the in vitro IC 50 value for growth inhibition. In contrast, sulindac generated plasma and tumor levels of SS that were appreciably less than the IC 50 value for tumor cell growth inhibition. These results support the feasibility of chemically modifying sulindac to design out COX associated toxicities, while increasing anticancer efficacy. Newer sulindac derivatives with higher potency and target selectivity, as well as formulations to improve oral bioavailability are being developed for colon cancer chemoprevention. Funding provided by NIH/NCI grants CA131378 and CA148817. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1865. doi:10.1158/1538-7445.AM2011-1865" @default.
• W2317334758 created "2016-06-24" @default.
• W2317334758 creator A5006292933 @default.
• W2317334758 creator A5016292580 @default.
• W2317334758 creator A5021533593 @default.
• W2317334758 creator A5022569332 @default.
• W2317334758 creator A5034358215 @default.
• W2317334758 creator A5051171177 @default.
• W2317334758 creator A5051362659 @default.
• W2317334758 creator A5056211347 @default.
• W2317334758 creator A5058307881 @default.
• W2317334758 creator A5058429452 @default.
• W2317334758 creator A5064917276 @default.
• W2317334758 creator A5066715892 @default.
• W2317334758 creator A5068169717 @default.
• W2317334758 creator A5071802884 @default.
• W2317334758 creator A5074047848 @default.
• W2317334758 creator A5076077003 @default.
• W2317334758 creator A5076699095 @default.
• W2317334758 creator A5087976717 @default.
• W2317334758 date "2011-04-15" @default.
• W2317334758 modified "2023-09-25" @default.
• W2317334758 title "Abstract 1865: Colon cancer chemopreventive properties of a non-cyclooxygenase inhibitory amide derivative of sulindac" @default.
• W2317334758 doi "https://doi.org/10.1158/1538-7445.am2011-1865" @default.
• W2317334758 hasPublicationYear "2011" @default.
• W2317334758 type Work @default.
• W2317334758 sameAs 2317334758 @default.
• W2317334758 citedByCount "0" @default.
• W2317334758 crossrefType "proceedings-article" @default.
• W2317334758 hasAuthorship W2317334758A5006292933 @default.
• W2317334758 hasAuthorship W2317334758A5016292580 @default.
• W2317334758 hasAuthorship W2317334758A5021533593 @default.
• W2317334758 hasAuthorship W2317334758A5022569332 @default.
• W2317334758 hasAuthorship W2317334758A5034358215 @default.
• W2317334758 hasAuthorship W2317334758A5051171177 @default.
• W2317334758 hasAuthorship W2317334758A5051362659 @default.
• W2317334758 hasAuthorship W2317334758A5056211347 @default.
• W2317334758 hasAuthorship W2317334758A5058307881 @default.
• W2317334758 hasAuthorship W2317334758A5058429452 @default.
• W2317334758 hasAuthorship W2317334758A5064917276 @default.
• W2317334758 hasAuthorship W2317334758A5066715892 @default.
• W2317334758 hasAuthorship W2317334758A5068169717 @default.
• W2317334758 hasAuthorship W2317334758A5071802884 @default.
• W2317334758 hasAuthorship W2317334758A5074047848 @default.
• W2317334758 hasAuthorship W2317334758A5076077003 @default.
• W2317334758 hasAuthorship W2317334758A5076699095 @default.
• W2317334758 hasAuthorship W2317334758A5087976717 @default.
• W2317334758 hasConcept C121608353 @default.
• W2317334758 hasConcept C126322002 @default.
• W2317334758 hasConcept C181199279 @default.
• W2317334758 hasConcept C185592680 @default.
• W2317334758 hasConcept C190283241 @default.
• W2317334758 hasConcept C202751555 @default.
• W2317334758 hasConcept C2776241388 @default.
• W2317334758 hasConcept C2778484676 @default.
• W2317334758 hasConcept C2779689624 @default.
• W2317334758 hasConcept C502942594 @default.
• W2317334758 hasConcept C526805850 @default.
• W2317334758 hasConcept C54355233 @default.
• W2317334758 hasConcept C55493867 @default.
• W2317334758 hasConcept C62112901 @default.
• W2317334758 hasConcept C62826618 @default.
• W2317334758 hasConcept C71924100 @default.
• W2317334758 hasConcept C81885089 @default.
• W2317334758 hasConcept C86803240 @default.
• W2317334758 hasConcept C98274493 @default.
• W2317334758 hasConceptScore W2317334758C121608353 @default.
• W2317334758 hasConceptScore W2317334758C126322002 @default.
• W2317334758 hasConceptScore W2317334758C181199279 @default.
• W2317334758 hasConceptScore W2317334758C185592680 @default.
• W2317334758 hasConceptScore W2317334758C190283241 @default.
• W2317334758 hasConceptScore W2317334758C202751555 @default.
• W2317334758 hasConceptScore W2317334758C2776241388 @default.
• W2317334758 hasConceptScore W2317334758C2778484676 @default.
• W2317334758 hasConceptScore W2317334758C2779689624 @default.
• W2317334758 hasConceptScore W2317334758C502942594 @default.
• W2317334758 hasConceptScore W2317334758C526805850 @default.
• W2317334758 hasConceptScore W2317334758C54355233 @default.
• W2317334758 hasConceptScore W2317334758C55493867 @default.
• W2317334758 hasConceptScore W2317334758C62112901 @default.
• W2317334758 hasConceptScore W2317334758C62826618 @default.
• W2317334758 hasConceptScore W2317334758C71924100 @default.
• W2317334758 hasConceptScore W2317334758C81885089 @default.
• W2317334758 hasConceptScore W2317334758C86803240 @default.
• W2317334758 hasConceptScore W2317334758C98274493 @default.
• W2317334758 hasLocation W23173347581 @default.
• W2317334758 hasOpenAccess W2317334758 @default.
• W2317334758 hasPrimaryLocation W23173347581 @default.
• W2317334758 hasRelatedWork W1965741093 @default.
• W2317334758 hasRelatedWork W1972079959 @default.
• W2317334758 hasRelatedWork W1995883964 @default.
• W2317334758 hasRelatedWork W2007597753 @default.
• W2317334758 hasRelatedWork W2013837833 @default.
• W2317334758 hasRelatedWork W2022061576 @default.
• W2317334758 hasRelatedWork W2065362284 @default.
• W2317334758 hasRelatedWork W2094658190 @default.
• W2317334758 hasRelatedWork W2095927721 @default.
• W2317334758 hasRelatedWork W2126602752 @default.
• W2317334758 hasRelatedWork W2182671498 @default.
• W2317334758 hasRelatedWork W2256204827 @default.

• next